Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

12.67 +0.80 (+6.74%)
Streaming Delayed Price Updated: 11:56 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent Biosolutions

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Why Emergent BioSolutions Stock Is Falling Again Today
An analyst lowered his price target on the stock. 
Via The Motley Fool
Exposures COVID-19
Stocks That Hit 52-Week Lows On Thursday
On Thursday morning, 5 companies achieved new lows for the year. Interesting Points: Emergent BioSolutions (NYSE:EBS) was the largest, in terms of market cap, to... 
Via Benzinga
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
From The Rosen Law Firm, P.A.
Via Business Wire
FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training
The FDA concluded its inspection of Emergent BioSolutions Inc’s (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped... 
Via Benzinga
Exposures COVID-19 Product Safety
House Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify
A congressional panel has launched an investigation into whether Emergent BioSolutions Inc (NYSE: EBS) was improperly awarded a $628 million federal... 
Via Benzinga
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent Biosolutions Inc. - EBS
From Kahn Swick & Foti, LLC
Via Business Wire
EMA Finds Potential Blood Clot Link With JNJ COVID-19 Shot, Adds Safety Warning
The European Medicines Agency’s (EMA) safety committee said that the Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine has possible links to... 
Via Benzinga
Exposures COVID-19
Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility
Emergent BioSolutions Inc (NYSE: EBS) has had a tough month: First, the company ruined 15 million doses of Johnson & Johnson’s (NYSE:... 
Via Benzinga
Exposures Product Safety
Why Emergent BioSolutions Stock Is Tumbling Today
The company has halted production of COVID-19 vaccines at its Baltimore facility as an FDA inspection moves forward. 
Via The Motley Fool
Exposures COVID-19 Product Safety
Why Emergent BioSolutions Stock Fell Today
The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact. 
Via The Motley Fool
Exposures COVID-19
EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. is Investigating Emergent BioSolutions, Inc. on Behalf of Emergent Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded
AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now,... 
Via Benzinga
Exposures COVID-19
Trouble Is Brewing For J&J's Covid Vaccine — What You Need To Know
European regulators are investigating four cases of blood clots in recipients of J&J's coronavirus vaccine. In response, JNJ stock dipped Friday. 
Via Investor's Business Daily
Exposures COVID-19
US Allocates Significantly Lower Number Of J&J Vaccines To States For Next Week: Reuters
The U.S. government will allot around 85% less Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccines to states next week, data from the Centers for Disease... 
Via Benzinga
Exposures COVID-19
Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)
From Entwistle & Cappucci LLP
Via Business Wire
AstraZeneca Stock Plagued As Issues Continue To Mount For Covid Vaccine
AstraZeneca stock dipped Wednesday after European regulators found a possible link between the company's Covid vaccine and rare cases of blood clots. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021
Upgrades According to Janney Capital, the prior rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) was changed from Neutral to Buy. Texas Capital Bancshares earned $1.... 
Via Benzinga
31 Stocks Moving in Thursday's Pre-Market Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) rose 44.4% to $10.73 in pre-market trading after the company, and EMC Pharma, announced an exclusive partnership to expand... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.